There is substantial evidence to show that the efficacy of CTX is related to its ability to cross the BBB as well as its high tumor-binding function mediated by the molecular targets namely, chloride channels, MMP-2, annexin A2, and recently, ERα and NRP-1. The gene discussed is NRP1; the disease is neoplasm.